Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%

Novo Nordisk's IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.